Safety Study of GPX-150 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Advanced Solid Tumors - Phase 1 Population
Interventions
DRUG

GPX-150 for Injection

Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.

Trial Locations (1)

52242

University of Iowa Hospital and Clinics, Iowa City

Sponsors
All Listed Sponsors
lead

Gem Pharmaceuticals

INDUSTRY